Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells

Cancer Letters

Volumn 189, Issue 2, 2003, Pages 197-206

  Hong, JangJa ^a,b   Ishihara, Kenji ^a   Yamaki, Kouya ^a   Hiraizumi, Kenji ^a   Ohno, Tadao ^c   Ahn, Jong Woong ^d   Zee, OkPyo ^b   Ohuchi, Kazuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Sungkyunkwan University   (South Korea)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^d Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Apicidin; CD11b; Differentiation; Histone deacetylase; HL 60 cell; Trichostatin A

Indexed keywords

APICIDIN; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; HISTONE DEACETYLASE INHIBITOR; NITROBLUE TETRAZOLIUM; TRICHOSTATIN A;

ACETYLATION; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVITY; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ACETYLATION; ANTIGENS, CD11B; ANTIGENS, CD14; ANTIGENS, CD15; APOPTOSIS; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HL-60 CELLS; HUMANS; K562 CELLS; NEOPLASM PROTEINS; PEPTIDES, CYCLIC; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 0037469090     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00500-1     Document Type: Article

References (42)

1. Klug A., Rhodes D., Smith J., Finch J.T., Thomas J.O. A low resolution structure for the histone core of the nucleosome. Nature. 287:1980;509-516.
2. Csordas A. On the biological role of histone acetylation. Biochem. J. 265:1990;23-38.
3. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 389:1997;349-352.
4. Pazin M.J., Kadonaga J.T. What's up and down with histone deacetylation and transcription? Cell. 89:1997;325-328.
5. McGhee J.D., Felsenfeld G. Nucleosome structure. Annu. Rev. Biochem. 49:1980;1115-1156.
6. Norton V.G., Marvin K.W., Yau P., Bradbury E.M. Nucleosome linking number change controlled by acetylation of histones H3 and H4. J. Biol. Chem. 265:1990;19848-19852.
7. Lee D.Y., Hayes J.J., Pruss D., Wolffe A.P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell. 72:1993;73-84.
8. Koyama Y., Adachi M., Sekiya M., Takekawa M., Imai K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood. 96:2000;1490-1495.
9. Riggs M.G., Whittaker R., Neumann J.R., Ingram V.M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature. 268:1977;462-464.
10. Cioe L., McNab A., Hubbell H.R., Meo P., Curtis P., Rovera G. Differential expression of the globin genes in human leukemia K562(S) cells induced to differentiate by hemin or butyric acid. Cancer Res. 41:1981;237-243.
11. Hoessly M.C., Rossi R.M., Fischkoff S.A. Factors responsible for variable reported lineages of HL-60 cells induced to mature with butyric acid. Cancer Res. 49:1989;3594-3597.
12. Kijima M., Yoshida M., Sugita K., Horinouchi S., Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268:1993;22429-22435.
13. Yoshida M., Nomura S., Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res. 47:1978;3688-3691.
14. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265:1990;17174-17179.
15. Kwon H.J., Owa T., Hassig C.A., Shimada J., Schreiber S.L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA. 95:1998;3356-3361.
16. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA. 96:1999;4592-4597.
17. Darkin-Rattray S.J., Gurnett A.M., Myers R.W., Dulski P.M., Crumley T.M., Allocco J.J., Cannova C., Meinke P.T., Colletti S.L., Bednarek M.A., Singh S.B., Goetz M.A., Dombrowski A.W., Polishook J.D., Schmatz D.M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA. 93:1996;13143-13147.
18. WAF1/Cip1 and gelsolin. Cancer Res. 60:2000;6068-6074.
19. Kim M.S., Son M.W., Kim W.B., In Park Y., Moon A. Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 157:2000;23-30.
20. Park J.S., Lee K.R., Kim J.C., Lim S.H., Seo J.A., Lee Y.W. A hemorrhagic factor (apicidin) produced by toxic Fusarium isolates from soybean seeds. Appl. Environ. Microbiol. 65:1999;126-130.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
22. Koay D.C., Sartorelli A.C. Functional differentiation signals mediated by distinct regions of the cytoplasmic domain of the granulocyte colony-stimulating factor receptor. Blood. 93:1999;3774-3784.
23. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., Lee H.Y., Lee Y.W., Lee H.W., Han J.W. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277:2002;2073-2080.
24. Collins S.J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood. 70:1987;1233-1244.
25. 3 or 12-O-tetradecanoylphorbol-13-acetate. Leukemia Res. 22:1998;537-547.
26. Collins S.J., Ruscetti F.W., Gallagher R.E., Gallo R.C. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc. Natl. Acad. Sci. USA. 75:1978;2458-2462.
27. Fischkoff S.A., Papuchis G.C., Nickols W.A. Decreased activity of acetyl-CoA carboxylase during chemically induced neutrophilic differentiation of human promyelocytic leukemia cells. J. Cell. Biochem. 26:1984;75-81.
28. Lotem J., Sachs L. Regulation of normal differentiation in mouse and human myeloid leukemic cells by phorbol esters and the mechanism of tumor promotion. Proc. Natl. Acad. Sci. USA. 76:1979;5158-5162.
29. 3 and the effect of interferon γ J. Leukoc. Biol. 54:1993;40-46.
30. Asou H., Koike M., Elstner E., Cambell M., Le J., Uskokovic M.R., Kamada N., Koeffler H.P. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood. 92:1998;2441-2449.
31. Fischkoff S.A., Pollak A., Gleich G.J., Testa J.R., Misawa S., Reber T.J. Eosinophilic differentiation of the human promyelocytic leukemia cell line, HL-60. J. Exp. Med. 160:1984;179-196.
32. Fischkoff S.A., Condon M.E. Switch in differentiative response to maturation inducers of human promyelocytic leukemia cells by prior exposure to alkaline conditions. Cancer Res. 45:1985;2065-2069.
33. Fischkoff S.A., Brown G.E., Pollak A. Synthesis of eosinophil-associated enzymes in HL-60 promyelocytic leukemia cells. Blood. 68:1986;185-192.
34. Jiang H., Lin J., Su Z.Z., Collart F.R., Huberman E., Fisher P.B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 9:1994;3397-3406.
35. Ho P.T., King I., Sartorelli A.C. Transcriptional regulation of the transferrin receptor in differentiating HL-60 leukemic cells. Biochem. Biophys. Res. Commun. 138:1986;995-1000.
36. Ho P.T., Ishiguro K., Sartorelli A.C. Regulation of transferrin receptor in myeloid and monocytic differentiation of HL-60 leukemia cells. Cancer Res. 49:1989;1989-1995.
37. Greenblatt M.S., Elias L. The type B receptor for tumor necrosis factor-α mediates DNA fragmentation in HL-60 and U937 cells and differentiation in HL-60 cells. Blood. 80:1992;1339-1346.
38. He Q., Jiang D. A novel aminosteroid is active for proliferation inhibition and differentiation induction of human acute myeloid leukemia HL-60 cells. Leukemia Res. 23:1999;369-372.
39. Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T., Tanimoto M., Murate T., Kawashima K., Saito H., Naoe T. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 13:1999;1316-1324.
40. Pahl H.L., Rosmarin A.G., Tenen D.G. Characterization of the myeloid-specific CD11b promoter. Blood. 79:1992;865-870.
41. Pahl H.L., Scheibe R.J., Zhang D.E., Chen H.M., Galson D.L., Maki R.A., Tenen D.G. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J. Biol. Chem. 268:1993;5014-5120.
42. Chen H.M., Pahl H.L., Scheibe R.J., Zhang D.E., Tenen D.G. The Sp1 transcription factor binds the CD11b promoter specifically in myeloid cells in vivo and is essential for myeloid-specific promoter activity. J. Biol. Chem. 268:1993;8230-8239.